Urinary tract infections (UTIs) are among the most common bacterial infections in women. More than 50% of women will experience at least one UTI in their lifetime, and approximately 27% have a symptomatic recurrence within six months of their initial episode1,2. While many may assume that UTIs are “simple” or easily treated, the reality is very different for many that face recurrent infections. For these women, UTIs can cause relentless pain, disturb sleep, reduced productivity at work or school, and significantly affect mental health. Far from being a minor inconvenience, they can dominate daily life and erode wellbeing. When inadequately treated or repeatedly mismanaged, UTIs can progress to acute pyelonephritis, a bacterial infection causing renal inflammation, which carries risks of hospitalisation and sepsis. In vulnerable groups, including pregnant women, untreated infections are associated with preterm birth, low birth weight, and maternal complications. These more serious outcomes are often overlooked in routine care, contributing to delays in diagnosis and treatment3.
The gender bias in UTI care
A critical challenge for women with recurrent UTIs is not the infection alone, but the systemic way their symptoms are handled. Reports consistently show that women’s concerns are frequently minimised or attributed to anxiety or poor hygiene, leading to delays in diagnosis and inadequate treatment. Too often, women are dismissed4 and told to “drink more water” or to “stop worrying.” This form of medical gaslighting has serious consequences. When symptoms are trivialised, diagnosis and treatment are delayed. Women are left to endure repeated infections, which can lead to isolation, frustration, and stigma5. Beyond the psychological toll of isolation, frustration, and stigma, recurrent UTIs can also disrupt immune function. Persistent infection drives chronic immune activation, which may contribute to bladder wall inflammation and tissue irritation. Over time, continuous exposure to infection keeps the immune system in a constant state of alert. This long-term strain can exhaust immune cells, making them less effective at fighting new infections. When the immune system stays activated for too long, it can become unbalanced. This constant inflammation doesn’t just affect the bladder, it can spread signals throughout the body that make women feel tired, unwell, or more prone to other health issues. These cascading effects illustrate that recurrent UTIs are not a minor inconvenience, they represent a significant health problem with local and systemic implications for women6.
The inequity becomes even clearer when considering gender differences. Because of male anatomy, men experience UTIs far less frequently. Historically, much of medical research and clinical training has been modelled around male physiology, meaning conditions that predominantly affect women have received less attention. This imbalance has shaped clinical environments where women’s pain is more likely to be downplayed or insufficiently investigated. Recognising how these biases originated is essential for improving equity in the diagnosis and management of UTIs.
Antimicrobial resistance and UTIs
The growing crisis of antimicrobial resistance (AMR), or what we commonly refer to as superbugs – hard-to-treat bacteria – is making UTIs even more difficult to treat7. For decades, UTIs were managed effectively with short courses of antibiotics. But today, these treatments are no longer guaranteed to work. Bacteria are evolving resistance, meaning the same medicines that once cleared an infection now often fail7. This has far-reaching consequences: infections last longer, complications become more likely, and patients may need more targeted antibiotics. AMR has transformed UTIs from a straightforward clinical problem into part of a global health challenge. What was once considered “simple” is now becoming a complex and pressing medical issue8.
Building a better future for UTI diagnosis and care
To drive this forward, we need to look at UTIs from three perspectives: science, medicine, and society. From a scientific standpoint, there is a clear need for rapid diagnostics that can identify the cause of infection quickly, and precision treatments that deliver targeted and effective therapies. Innovations in rapid diagnostics9, which analyse the genetic material of microbes, hold great promise, and the goal is simple: faster answers and more tailored care. For medicine, patient-centred care must be the standard. Listening to women, validating their experiences, and ensuring timely treatment are fundamental. A UTI should never be brushed aside and women need to feel comfortable discussing their pain with their doctor – no pain should be ignored. On a societal level, outdated attitudes need to be challenged. Advocacy and awareness are crucial, but so is empowering patients to advocate for themselves. This might mean patients asking for a urine culture to confirm the cause of infection, requesting a referral to a specialist when symptoms persist, or simply insisting that recurrent UTIs deserve serious attention. Patients have the right to be heard and to seek the care they need.
What needs to change?
First, we must invest in research and innovation to bring new tools and treatments to the clinic. Second, clinical pathways for recurrent UTIs need to be improved, so women receive faster and more effective care. Third, women’s voices must be amplified, as their stories matter and can drive change. Most importantly, UTIs must be recognised for what they are: a serious health issue, not “just an inconvenience”. By combining data, science, medicine, and advocacy, we can move toward a future where women no longer suffer in silence and where treatment is both effective and equitable.
References
- Medina, M., & Castillo-Pino, E. (2019). An introduction to the epidemiology and burden of urinary tract infections. Therapeutic Advances in Urology, 11(1), 175628721983217. https://doi.org/10.1177/1756287219832172
- Advani, S. D., Thaden, J. T., Perez, R., Stair, S. L., Lee, U. J., & Siddiqui, N. Y. (2025). State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women. Clinical Infectious Diseases, 80(3), e31–e42. https://doi.org/10.1093/cid/ciae653
- Czajkowski, K., Broś-Konopielko, M., & Teliga-Czajkowska, J. (2021). Urinary tract infection in women. Menopausal Review, 20(1), 40–47. https://doi.org/10.5114/pm.2021.105382
- Leydon, G. M., Turner, S., Smith, H., & Little, P. (2010). Women’s views about management and cause of urinary tract infection: qualitative interview study. BMJ, 340(feb05 1), c279–c279. https://doi.org/10.1136/bmj.c279
- Grigoryan, L., Mulgirigama, A., Powell, M., & Schmiemann, G. (2022). The emotional impact of urinary tract infections in women: a qualitative analysis. BMC Women’s Health, 22(1). https://doi.org/10.1186/s12905-022-01757-3
- Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary Tract infections: epidemiology, Mechanisms of Infection and Treatment Options. Nature Reviews Microbiology, 13(5), 269–284. https://doi.org/10.1038/nrmicro3432
- Pothoven, R. (2023). Management of urinary tract infections in the era of antimicrobial resistance. Drug Target Insights, 17(1), 126–137. https://doi.org/10.33393/dti.2023.2660
- Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., Hsu, R. L., Chalek, J., Araki, D. T., Chung, E., Raggi, C., Gershberg Hayoon, A., Davis Weaver, N., Lindstedt, P. A., Smith, A. E., & Altay, U. (2024). Global Burden of Bacterial Antimicrobial Resistance 1990–2021: a Systematic Analysis with Forecasts to 2050. The Lancet, 404(10459), 1199–1226. https://doi.org/10.1016/s0140-6736(24)01867-1
- Forbes, J. D., Knox, N. C., Peterson, C.-L., & Reimer, A. R. (2018). Highlighting Clinical Metagenomics for Enhanced Diagnostic Decision-making: A Step Towards Wider Implementation. Computational and Structural Biotechnology Journal, 16, 108–120. https://doi.org/10.1016/j.csbj.2018.02.006